Lesson plan
2CB-2OCD3
2CB-2OCD 3 , also known as 2-trideuteromethoxy-2C-B, is a serotonin 5-HT 2A receptor agonist and possible psychedelic drug of the phenethylamine and 2C families. It is the isotopologue of 2C-B in which the three hydrogen atoms of the methoxy group at the 2 position have been replaced with the deuterium isotopes. The drug shows similar serotonin 5-HT 2A receptor pharmacodynamics and metabolism as 2C-B in vitro. The chemical synthesis of 2CB-2OCD 3 has been described. 2CB-2OCD 3 was developed by Nicholas V. Cozzi and Paul F. Daley of the Alexander Shulgin Research Institute (ASRI). It was patented in 2024 and was first described in the scientific literature in 2026.
Article summary
2CB-2OCD 3 , also known as 2-trideuteromethoxy-2C-B, is a serotonin 5-HT 2A receptor agonist and possible psychedelic drug of the phenethylamine and 2C families. It is the isotopologue of 2C-B in which the three hydrogen atoms of the methoxy group at the 2 position have been replaced with the deuterium isotopes. The drug shows similar serotonin 5-HT 2A receptor pharmacodynamics and metabolism as 2C-B in vitro. The chemical synthesis of 2CB-2OCD 3 has been described. 2CB-2OCD 3 was developed by Nicholas V. Cozzi and Paul F. Daley of the Alexander Shulgin Research Institute (ASRI). It was patented in 2024 and was first described in the scientific literature in 2026.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.